Astrazeneca (AZN) Other Operating Expenses (2009 - 2026)

Astrazeneca's Other Operating Expenses history runs 18 years deep, the most recent figure standing at $152.0 million for Q2 2026.

• In Q2 2026, Other Operating Expenses rose 92.41% year-over-year to $152.0 million; the TTM figure through Jun 2026 stood at $530.0 million (up 67.19% YoY), while the FY2025 annual figure was $381.0 million, up 51.19% from the prior year.
• Other Operating Expenses for Q2 2026 stood at $152.0 million, down from $189.0 million in the prior quarter.
• The five-year high for Other Operating Expenses was $1.2 billion in Q4 2023, with the low at $25.0 million in Q3 2024.
• The 5-year median for Other Operating Expenses is $103.0 million (2022), against an average of $219.7 million.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses surged 552.38% in 2023, then tumbled 92.35% in 2024.
• Astrazeneca's Other Operating Expenses stood at $189.0 million in 2022, then soared by 552.38% to $1.2 billion in 2023, then slumped by 91.89% to $100.0 million in 2024, then changed by 0.0% to $100.0 million in 2025, then surged by 52.0% to $152.0 million in 2026.
• Business Quant data shows AZN's Other Operating Expenses at $152.0 million in Q2 2026, $189.0 million in Q1 2026, and $100.0 million in Q4 2025.